X0609 4 2026-09-04 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0002009762 Budur Kumar false 630 W GERMANTOWN PIKE PLYMOUTH MEETING PA 19462 false true false false CHIEF MEDICAL OFFICER 0 Common Stock 2026-09-04 4 S 0 5500 41.9839 D 18615 D Common Stock 2026-09-08 4 S 0 4500 42.2475 D 14115 D Common Stock 2026-09-08 4 S 0 1000 42.7947 D 13115 D Common Stock 2026-09-08 4 M 0 12200 30.69 A 25315 D Common Stock 2026-09-08 4 M 0 10754 30.27 A 36069 D Common Stock 2026-09-08 4 S 0 22954 43.1014 D 13115 D Stock Option 30.69 2026-09-08 4 M 0 12200 0 D 2034-01-24 Common Stock 12200 30300 D Stock Option 30.27 2026-09-08 4 M 0 10754 0 D 2034-05-01 Common Stock 10754 64246 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.32. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.59 to $42.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $43.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. /s/ Christian Ulrich, Attorney-in-Fact 2026-09-09